/XBIT
XBIT Stock - XBiotech Inc.
Healthcare|BiotechnologyNASDAQ
$2.50-1.19%
$0.03 (-1.19%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.37
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XBIT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.48 – $2.52
TARGET (TP)$2.88
STOP LOSS$2.30
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$5.11
52W Low$2.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $4.01M | $18.39M | $44.00M |
| Gross Profit | N/A | N/A | $3.36M | $12.57M | $9.45M |
| Gross Margin | N/A | N/A | 83.8% | 68.4% | 21.5% |
| Operating Income | $-42,471,000 | $-37,510,000 | $-34,490,000 | $-25,082,000 | $-18,276,000 |
| Net Income | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 | $-11,221,000 |
| Net Margin | N/A | N/A | -820.4% | -94.7% | -25.5% |
| EPS | $-1.26 | $-0.81 | $-1.08 | $-0.58 | $-0.36 |
Company Overview
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XBITBeat Rate
0%
Last 3 quarters
Avg Surprise
-761.1%
EPS vs Estimate
Beats / Misses
0/3
Last 12 quarters
Latest EPS
$-0.20
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $-0.20 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.06 | — | — |
Q2 2025 | May 14, 2025 | — | $-0.36 | — | — |
Q1 2025 | Mar 18, 2025 | — | $-0.34 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-0.16 | — | — |
Q3 2024 | Aug 12, 2024 | — | $-0.43 | — | — |
Q2 2024 | May 10, 2024 | — | $-0.33 | — | — |
Q1 2024 | Mar 15, 2024 | — | $-0.16 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.24 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-0.29 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.13 | — | — |
Q1 2023 | Mar 15, 2023 | — | $-0.10 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.42 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-0.38 | — | — |
Q2 2022 | May 10, 2022 | — | $-0.18 | — | — |
Q1 2022 | Mar 15, 2022 | $0.02 | $-0.21 | -1150.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.03 | $-0.11 | -466.7% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $0.03 | $-0.17 | -666.7% | ✗ MISS |
Frequently Asked Questions about XBIT
What is XBIT's current stock price?
XBiotech Inc. (XBIT) is currently trading at $2.50 per share. The stock has moved -1.19% today.
What is the analyst price target for XBIT?
No analyst price targets are currently available for this stock.
What sector is XBiotech Inc. in?
XBiotech Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XBIT's market cap?
XBiotech Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does XBIT pay dividends?
No, XBiotech Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
Explore stocks similar to XBIT for comparison